Patient and Physician Perspectives on Non-Alcoholic Fatty Liver Disease

Patient and Physician Perspectives on Non-Alcoholic Fatty Liver Disease (NAFLD)

This trial studies patient and physician perspectives on non-alcoholic fatty liver disease. Using questionnaires and interviews, this trial may help researchers understand physicians' knowledge about the diagnosis, prognosis, treatment and management of non-alcoholic fatty liver disease, as well as gain an in-depth understanding of Hispanic patients' perceptions about the disease and investigate how cultural factors may play a role in its diagnosis, treatment and management.

Study Overview

• Status: Active, not recruiting
• Conditions: Nonalcoholic Fatty Liver Disease; Physician
• Intervention / Treatment: Other: Questionnaire Administration; Other: Interview

Detailed Description

PRIMARY OBJECTIVES:

I. Explore the perceptions of non-alcoholic fatty liver disease (NAFLD), including knowledge, current practices for diagnosis and management, and additional disease-related perceptions amongst both primary care physicians.

II. Explore the perceptions of NAFLD, including knowledge, diagnosis and management, and additional disease-related perceptions amongst Hispanic patients.

OUTLINE:

Patients and physicians complete a questionnaire over 5 minutes and an interview over 30-45 minutes about thoughts on NAFLD, including what they know about NAFLD and its diagnosis, management, and monitoring, and other thoughts on NAFLD.

• Study Type: Observational
• Enrollment (Actual): 17

Contacts and Locations

• Study Contact: Name: Natalia Hederia; Phone Number: 713-792-2250; Email: NIHeredia@mdanderson.org

Study Locations

• United States
  • Texas
    • Houston, Texas, United States, 77030
      • M D Anderson Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Hispanic patients with NAFLD from the Greater Houston Metropolitan Area and practicing physicians, who are primary care physicians (internal medicine, family medicine, etc.)

Description

Inclusion Criteria:

• Be a self-reported practicing physician, who is a primary care physician (internal medicine, family medicine, etc.)
• Self-reported Hispanic ethnicity from the Greater Houston Metropolitan Area (patient)
• Have been diagnosed with NAFLD by a doctor (patient)
• Be an adult >/= 18 (patient)
• Able to speak English (patient)

Exclusion Criteria

-None

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Observational (questionnaire, interview); Patients and physicians complete a questionnaire over 5 minutes and an interview over 30-45 minutes about thoughts on NAFLD, including what they know about NAFLD and its diagnosis, management, and monitoring, and other thoughts on NAFLD.	Other: Questionnaire Administration; Complete questionnaire; Other: Interview; Complete interview

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Explore the perceptions of NAFLD, including knowledge, current practices for diagnosis and management, and additional disease-related perceptions amongst both primary care physicians (Questionnaire)	Up to 1 year
Explore the perceptions of NAFLD, including knowledge, diagnosis and management, and additional disease-related perceptions amongst Hispanic patients. (Questionnaire)	Up to 1 year

Collaborators and Investigators

• Sponsor: M.D. Anderson Cancer Center
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: Lorna McNeill, M.D. Anderson Cancer Center

Publications and helpful links

Helpful Links

• University of Texas MD Anderson Cancer Center Website

Study record dates

Study Major Dates

• Study Start (Actual): August 22, 2019
• Primary Completion (Estimated): May 1, 2030
• Study Completion (Estimated): May 1, 2030

Study Registration Dates

• First Submitted: October 4, 2019
• First Submitted That Met QC Criteria: October 16, 2019
• First Posted (Actual): October 18, 2019

Study Record Updates

• Last Update Posted (Actual): February 15, 2024
• Last Update Submitted That Met QC Criteria: February 13, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Liver Diseases; Fatty Liver; Non-alcoholic Fatty Liver Disease
• Other Study ID Numbers: 2019-0262 (Other Identifier: M D Anderson Cancer Center); NCI-2019-05886 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No